Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).

Frei, Christopher Raymond; Ryan, Kellie; Obodozie-Ofoegbu, Grace Oby; Moore, Amanda Marie; Teng, Chengwen; Lucero, Kana Tai; Davis, Laura Dean; Jones, Xavier Francisco; Nooruddin, Zohra.

Afiliação

Frei CR; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.
Ryan K; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Obodozie-Ofoegbu GO; South Texas Veterans Health Care System, San Antonio, TX, USA.
Moore AM; AstraZeneca US Medical Affairs, Gaithersburg, MD, USA.
Teng C; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.
Lucero KT; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Davis LD; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.
Jones XF; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.
Nooruddin Z; Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, The University of South Carolina, Columbia, SC, USA.

Leuk Lymphoma ; : 1-4, 2024 Jun 04.

Article em En | MEDLINE | ID: mdl-38832701

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article